Trevi Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Trevi Therapeutics, Inc. (TRVI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 0 shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-06
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 0.00 shares.
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 0.00 shares.
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was -13.85K shares.
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 0.00 shares, a 100.00% decline from fiscal 2024.
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 67.83K shares, a 71.42% decline from fiscal 2023.
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 237.33K shares, a 440.35% increase from fiscal 2022.
- Trevi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 43.92K shares, a 83.90% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 0.00 shares 10-Q · filed 2026-08-06 | 0.00 shares derived: sum of 3 quarters · filed 2026-08-06 | -13.85K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-05 | 0.00 shares derived: sum of 2 quarters · filed 2026-05-05 | -13.85K shares derived: sum of 3 quarters · filed 2026-05-05 | 0.00 shares derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -13.85K shares derived: sum of 2 quarters · filed 2026-03-17 | 0.00 shares derived: sum of 3 quarters · filed 2026-03-17 | 0.00 shares 10-K · filed 2026-03-17 |
| 2025-09-30 | -13.85K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 0.00 shares derived: sum of 2 quarters · filed 2025-11-13 | 0.00 shares 10-Q · filed 2025-11-13 | 0.00 shares derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | 13.85K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 13.85K shares 10-Q · filed 2025-08-07 | 13.85K shares derived: sum of 3 quarters · filed 2025-08-07 | 13.85K shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-08 | 0.00 shares derived: sum of 2 quarters · filed 2025-05-08 | 0.00 shares derived: sum of 3 quarters · filed 2025-05-08 | 39.11K shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | 0.00 shares derived: sum of 2 quarters · filed 2025-03-18 | 39.11K shares derived: sum of 3 quarters · filed 2025-03-18 | 67.83K shares 10-K · filed 2025-03-18 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 39.11K shares derived: sum of 2 quarters · filed 2024-11-06 | 67.83K shares 10-Q · filed 2024-11-06 | 70.28K shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 39.11K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 67.83K shares 10-Q · filed 2024-08-08 | 70.28K shares derived: sum of 3 quarters · filed 2024-08-08 | 97.42K shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 28.71K shares 10-Q · filed 2024-05-07 | 31.16K shares derived: sum of 2 quarters · filed 2024-05-07 | 58.31K shares derived: sum of 3 quarters · filed 2024-05-07 | 261.83K shares derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | 2.45K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | 29.60K shares derived: sum of 2 quarters · filed 2024-03-20 | 233.12K shares derived: sum of 3 quarters · filed 2024-03-20 | 237.33K shares 10-K · filed 2024-03-20 |
| 2023-09-30 | 27.15K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 230.66K shares derived: sum of 2 quarters · filed 2023-11-09 | 234.88K shares 10-Q · filed 2023-11-09 | 242.50K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 203.52K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 207.73K shares 10-Q · filed 2023-08-10 | 215.35K shares derived: sum of 3 quarters · filed 2023-08-10 | 249.02K shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 4.21K shares 10-Q · filed 2023-05-11 | 11.84K shares derived: sum of 2 quarters · filed 2023-05-11 | 45.50K shares derived: sum of 3 quarters · filed 2023-05-11 | |
| 2022-12-31 | 7.62K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | 41.29K shares derived: sum of 2 quarters · filed 2023-03-16 | 43.92K shares 10-K · filed 2023-03-16 | |
| 2022-09-30 | 33.67K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 36.30K shares 10-Q · filed 2022-11-10 | ||
| 2022-06-30 | 2.63K shares 10-Q · filed 2022-08-11 | |||
| 2021-12-31 | 95.83K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | 271.61K shares derived: sum of 2 quarters · filed 2022-03-17 | 271.61K shares derived: sum of 3 quarters · filed 2022-03-17 | 272.76K shares 10-K · filed 2022-03-17 |
| 2021-09-30 | 175.78K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 175.78K shares derived: sum of 2 quarters · filed 2021-11-10 | 176.93K shares 10-Q · filed 2021-11-10 | 251.62K shares derived: sum of 4 quarters · filed 2021-11-10 |
| 2021-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | 1.15K shares 10-Q · filed 2021-08-12 | 75.83K shares derived: sum of 3 quarters · filed 2021-08-12 | |
| 2021-03-31 | 1.15K shares 10-Q · filed 2021-05-13 | 75.83K shares derived: sum of 2 quarters · filed 2021-05-13 | ||
| 2020-12-31 | 74.68K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | 86.53K shares 10-K · filed 2021-03-25 | ||
| 2020-09-30 | 11.84K shares 10-Q · filed 2020-11-12 | |||
| 2019-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | 767.00 shares derived: sum of 2 quarters · filed 2020-11-12 | 6.36K shares 10-K · filed 2020-03-16 | |
| 2019-09-30 | 767.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | 6.36K shares 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | 5.59K shares 10-Q · filed 2019-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |